NEREUS™, first new motion sickness drug in 40+ years, now available in the US with direct-to-consumer ordering.

Vanda Pharmaceuticals has launched NEREUS™ (tradipitant), the first new prescription drug in over 40 years for preventing motion sickness-induced vomiting in adults. Approved by the FDA in December 2025, NEREUS™ works by blocking NK-1 receptors in the brain to stop vomiting triggered by motion. It is available nationwide through pharmacies and a direct-to-consumer platform at nereus.us, priced at $85 per dose via the portal, significantly lower than the standard $255 list price. This new treatment offers a modern solution for millions of Americans affected by motion sickness during travel by car, plane, or boat.